References
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480–91.
- Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, Demery G, et al. Gastroenterology services in the UK. The burden of disease and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut 2007;56:1–113.
- Spiller R, Camilleri M, Longstreth GF. Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? Clin Gastroenterol Hepatol 2010;8:125–36.
- Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–90.
- National Institute for Health and Clinical Excellence. Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. Full guidance. CG61. London: National Institute for Health and Clinical Excellence; 2008. http://www.nice.org.uk/nicemedia/pdf/IBSFullFuideline.pdf.
- Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.
- Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
- Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012;12:5.
- Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615–21.
- Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.
- Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506–13.
- Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009;24:49–55.
- Faecal calprotectin diagnostic tests to differentiate inflammatory bowel disease from irritable bowel syndrome, NICE. http://guidance.nice.org.uk/DT/12#keydocs.
- Department of Health. Value of calprotectin in screening out irritable bowel syndrome (09041 and 09026). www.cep.dh.gov.uk/CEPProducts/Catalogue.aspx.
- Health and Wellbeing Joint Strategic Needs Assessment Summary. 2011. http://www.brightonandhovepct.nhs.uk/about/improving/keylocaldata/documents/BrightonandHoveJSNAsummary2011Finalversion.pdf.
- http://www.mapofmedicine.com/.
- Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:16–19.
- Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Chapter 8: Evaluating diagnostic tests. In Clinical epidemiology. 3rd edition. Lippincott Williams & Wilkins: 2006.
- Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450–60.
- Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.
- Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al. Foell faecal S100A12 as a non‐invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706–13.
- NHS payments by results 2008–09, National Tariff Information
- Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012;45:552–5.
- Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78–82.